---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-015897"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2022-06-01T23:59:59+00:00"
generated_at: "2026-06-25T05:25:39.034270+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Esperion appoints J. Martin Carroll as Chairperson of the Board and new director

## Summary
- J. Martin Carroll appointed to fill newly created vacancy; board expands from 9 to 10 directors.
- Carroll named Chairperson of the Board effective June 1, 2022.
- Carroll previously served as President/CEO of Boehringer Ingelheim Corporation and Merck & Co. veteran.
- Esperion reiterates expectation for CLEAR Outcomes topline data in Q1 2023.

## SEC filing metadata
- accession: 0001628280-22-015897
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2022-06-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828022015897/0001628280-22-015897-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828022015897/espr-20220601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-015897
- JSON: https://secwatch.observer/filing/0001628280-22-015897.json
- Plain text: https://secwatch.observer/filing/0001628280-22-015897.txt

## Key facts
- Executive change
  J. Martin Carroll was appointed as Chairperson of the Board at Esperion Therapeutics, Inc..
  - Action: appointed
  - Role: Chairperson of the Board
  source text: On June 1, 2022, the Board of Directors (the “Board”) of Esperion Therapeutics, Inc (the “Company”) elected J. Martin Carroll to fill in the newly created vacancy on the Board resulting from an increase in the size of the Board from nine (9) directors to ten (10) directors, effective June 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828022015897/0001628280-22-015897-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.